On November 6, 2026, a Phase 4 clinical trial update was recorded for the study titled "The Effects of Ferric Derisomaltose in Patients With Acute Heart Failure and Iron Deficiency on Exercise Capacity and Quality of Life" (COREVIVE-HFrEF). The trial is registered under identifier NCT05971732 and is listed with a status of recruiting.
This study is a Phase 4 trial, meaning it is being conducted after a therapy has already received regulatory approval, typically to gather further data in a defined patient population. The trial focuses on patients with acute heart failure who also have iron deficiency, examining outcomes related to exercise capacity and quality of life, according to the registered title.
No results, interim findings, or efficacy data have been reported for this trial as of this update. The current record reflects only the recruiting status and the scope of the study as registered.
Readers interested in background information on nesiritide, which carries an unapproved research status, can consult the compound overview for additional context.